Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 beta-lactamase conferring resistance to beta-lactamase inhibitors.
about
Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threatbeta-Lactamases in laboratory and clinical resistanceA functional classification scheme for beta-lactamases and its correlation with molecular structureDetection of OXA-1 β-lactamase gene of Klebsiella pneumoniae from blood stream infections (BSI) by conventional PCR and in-silico analysis to understand the mechanism of OXA mediated resistanceAmpicillin-sulbactam and amoxicillin-clavulanate susceptibility testing of Escherichia coli isolates with different beta-lactam resistance phenotypesInhibitor-resistant TEM beta-lactamases: phenotypic, genetic and biochemical characteristics.Antimicrobial susceptibilities and molecular epidemiology of Salmonella enterica serotype enteritidis strains isolated in Hong Kong from 1986 to 1996.Discriminatory detection of inhibitor-resistant beta-lactamases in Escherichia coli by single-strand conformation polymorphism-PCR.Phenotypic study of resistance of beta-lactamase-inhibitor-resistant TEM enzymes which differ by naturally occurring variations and by site-directed substitution at Asp276.Selection and characterization of beta-lactam-beta-lactamase inactivator-resistant mutants following PCR mutagenesis of the TEM-1 beta-lactamase geneAntifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.Molecular characterization of TEM-59 (IRT-17), a novel inhibitor-resistant TEM-derived beta-lactamase in a clinical isolate of Klebsiella oxytocaKinetic study of two novel enantiomeric tricyclic beta-lactams which efficiently inactivate class C beta-lactamases.TEM-80, a novel inhibitor-resistant beta-lactamase in a clinical isolate of Enterobacter cloacaeEx vivo pharmacodynamics of amoxicillin-clavulanate against beta-lactamase-producing Escherichia coli in a yucatan miniature pig model that mimics human pharmacokinetics.Clinical characteristics of bloodstream infections due to ampicillin-sulbactam-resistant, non-extended- spectrum-beta-lactamase-producing Escherichia coli and the role of TEM-1 hyperproduction.Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM beta-lactamases from clinical isolates of Escherichia coliIncidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli.First characterization of inhibitor-resistant TEM (IRT) beta-lactamases in Klebsiella pneumoniae strainsExtended-spectrum and inhibitor-resistant TEM-type beta-lactamases: mutations, specificity, and three-dimensional structure.Implication of Ile-69 and Thr-182 residues in kinetic characteristics of IRT-3 (TEM-32) beta-lactamaseA TEM-derived extended-spectrum beta-lactamase in Pseudomonas aeruginosa.Properties of IRT-14 (TEM-45), a newly characterized mutant of TEM-type beta-lactamases.A complex mutant of TEM-1 beta-lactamase with mutations encountered in both IRT-4 and extended-spectrum TEM-15, produced by an Escherichia coli clinical isolate.Construction and characterization of an OHIO-1 beta-lactamase bearing Met69Ile and Gly238Ser mutations.Inhibitor-resistant TEM (IRT) beta-lactamases with different substitutions at position 244Non-phenotypic tests to detect and characterize antibiotic resistance mechanisms in Enterobacteriaceae.Spanish multicenter study of the epidemiology and mechanisms of amoxicillin-clavulanate resistance in Escherichia coli.Quantifying nonspecific TEM beta-lactamase (blaTEM) genes in a wastewater streamVariety of beta-lactamases produced by amoxicillin-clavulanate-resistant Escherichia coli isolated in the northeastern United States.WGS-based surveillance of third-generation cephalosporin-resistant Escherichia coli from bloodstream infections in Denmark.Construction and characterization of mutants of the TEM-1 beta-lactamase containing amino acid substitutions associated with both extended-spectrum resistance and resistance to beta-lactamase inhibitors.Properties of mutant SHV-5 beta-lactamases constructed by substitution of isoleucine or valine for methionine at position 69.Mutant TEM beta-lactamase producing resistance to ceftazidime, ampicillins, and beta-lactamase inhibitors.Beta-lactamases in ampicillin-resistant Escherichia coli isolates from foods, humans, and healthy animals.Prevalence of clinical isolates of Escherichia coli producing inhibitor-resistant beta-lactamases at a University Hospital in Barcelona, Spain, over a 3-year periodCatalytic properties of class A beta-lactamases: efficiency and diversity.High prevalence of fecal carriage of extended spectrum β-lactamase/AmpC-producing Enterobacteriaceae in cats and dogs.Study of the in vitro activity of amoxicillin/clavulanic acid and other beta-lactam antibiotics against Escherichia coli isolated from urine specimens.Probing active site chemistry in SHV beta-lactamase variants at Ambler position 244. Understanding unique properties of inhibitor resistance.
P2860
Q24550671-DAF337D8-D29F-45E0-84A3-98D26FCD6D2DQ24669605-F7BA0AE1-CB26-47E4-92DF-103509C0B8AFQ24677460-5B9FE034-6210-460B-92CB-F03E01D1BA8DQ28541123-8944BA40-FBC6-4AC7-89FF-C6510900FD35Q33548223-38109C8D-C2AE-49CB-93C8-81F102859C0DQ33647947-EFFACB04-608A-469B-97E7-9572976B3243Q33670355-887572AF-54DE-4A53-833C-2644B89FCB4BQ33692735-5E179EBF-6D02-42E3-BF54-59F7ED929C76Q33693187-690D095B-1016-4E17-9942-D501FE176378Q33693837-CCFF5475-446A-4EFD-B3A3-CF3284D02A60Q33749111-832179F1-74C1-44BB-A91D-581ED7FEE2A1Q33977130-8AE9310A-347D-42CF-B993-05010C2E81F2Q33982670-E74BEF03-7A82-430D-892A-E9A92992C3EDQ34106908-76F17888-DC95-4AC7-A153-BC0867E5386DQ34252545-2024AF00-2986-4B8D-BEFC-E9CC4ACAE33AQ34529235-E34E067A-AEB3-4B0B-B8FF-217E350A8594Q35111680-A8BD1CDE-DB1E-46CC-8872-B18535A913BEQ35120245-CCE68882-B19F-492C-A8E9-B8A6F401BA77Q35120452-2EAC8976-6D0F-44E7-81E5-423C51EB1B2EQ35120519-548B1BEF-673E-4758-A7C8-23CD71143C7EQ35128617-C541FE6D-135E-4AE4-AFC6-FBF0567D00ABQ35128838-C8A7234E-04B9-4E11-A683-82C215A67DA1Q35132416-B5A32E1F-DB4B-41F2-95D5-8B7EF7720BA7Q35136688-E3AAEFAD-9CBF-402E-855B-5BAC89C218B9Q35138077-0F974E41-16F0-4624-9990-A554E2647C07Q35139062-036706B8-0DD8-4CC3-895B-F7B308C28199Q35297743-3D3F5ADC-D46C-4FC6-A339-F32F08C2B27CQ36086480-8F218D05-4508-4FB5-8634-674A054A4A00Q37032925-6A0F5E85-3063-4EB7-8E02-3B695DD7919BQ37734137-FADF5CDD-BD17-48F7-B8D8-51D4373F813DQ38736107-5B17DB00-C36C-45F8-9C88-8F38F14FFC50Q39471431-125F78B2-8875-4015-B5B4-3B1F61C054EAQ39558648-652B4DA2-8EBA-4031-B181-31BE8BC893BBQ39652959-ED87E4DD-AD71-4D90-86BE-4A010978096DQ39658035-27C50D4C-8C1F-4537-A664-C907737908CCQ39671146-A4C18A79-C34F-4428-B5E6-ED98EB91CAA0Q40863105-C3C1F1E7-9C19-41CD-986D-41E1280AA34FQ42019900-DDD6E53E-EE8E-4427-9EB2-1D7E949C4397Q43578684-184880D1-220A-4F9F-998D-A616A81A7EBCQ43684255-84A11EA2-8AC3-4F4E-A333-DFBD9DB8344F
P2860
Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 beta-lactamase conferring resistance to beta-lactamase inhibitors.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Emergence of clinical isolates ...... to beta-lactamase inhibitors.
@ast
Emergence of clinical isolates ...... to beta-lactamase inhibitors.
@en
type
label
Emergence of clinical isolates ...... to beta-lactamase inhibitors.
@ast
Emergence of clinical isolates ...... to beta-lactamase inhibitors.
@en
prefLabel
Emergence of clinical isolates ...... to beta-lactamase inhibitors.
@ast
Emergence of clinical isolates ...... to beta-lactamase inhibitors.
@en
P2093
P2860
P356
P1476
Emergence of clinical isolates ...... to beta-lactamase inhibitors.
@en
P2093
P2860
P304
P356
10.1128/AAC.38.5.1085
P407
P577
1994-05-01T00:00:00Z